Post-Stroke Cognitive Impairment (PSCI)Repetitive Transcranial Magnetic Stimulation (rTMS)Stroke
Investigational drug(s) / intervention(s)
sham repetitive transcranial magnetic stimulationrepetitive transcranial magnetic stimulation
sham repetitive transcranial magnetic stimulation: The control group will undergo rTMS sham stimulation therapy combined with conventional rehabilitation treatment. They will use a sham stimulation coil, which means applying the same parameters and methods to stimulate the head. Although the sham stimulation coil has no difference in appearance and sound from the real stimulation coil, it cannot generate a real magnetic field to stimulate the brain.
repetitive transcranial magnetic stimulation: The stimulation site is the dorsolateral area of the left prefrontal lobe. The "8" shape coil is placed in contact with the scalp. The frequency is 10Hz, the repetition rate is 80% rMT. The stimulation lasts for 5 seconds, with an interval of 25 seconds. A total of 40 sets of stimulation are given, with a total of 2000 pulses. The treatment lasts for 20 minutes per day, for 20 days in total. A total of 20 interventions were completed. The experimental group will receive rTMS stimulation therapy, which involves applying high-frequency 10Hz rTMS to the patients' heads for 20 minutes, followed by conventional rehabilitation treatment.
Study summary
To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.
Eligibility
Sex
ALL
Min age
35 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. Meets the diagnostic criteria for stroke as stipulated in the "Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)", and the initial stroke diagnosis is confirmed by cranial CT or MRI examination, and is confirmed as the initial onset;
2. The disease course is 1-12 months;
3. Has cognitive impairment (MoCA \< 26 points, education years ≤ 12 years, add 1 point to the score result);
4. Age 35-75 years old, gender not limited;
5. Stable vital signs, no progressive neurological symptoms;
6. No severe aphasia, visual or auditory impairment, and able to complete the research protocol;
7. Not using antidepressant drugs simultaneously;
8. If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period;
9. Voluntarily participate and sign the informed consent form.
Exclusion Criteria:
1. Has a history of brain tumors, brain trauma, epilepsy or mental disorders;
2. Had cognitive impairment before the stroke;
3. Underwent craniotomy or had a skull defect;
4. Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.);
5. Has other serious diseases that may affect the study;
6. Pregnant women
Primary outcome measure(s)
Montreal Cognitive Assessment — Baseline, Day 10, Day 20,Evaluate the Montreal Cognitive Assessment Scale, fNIRS, Symbol-Digit Substitution Test, Shape Linking Test, Pittsburgh Sleep Quality Index, Digit Span Test, Stroop Test, Fugl-Meyer Assessment, Hamilton Depression Scale, Hamilton The total score of the Montreal Cognitive Assessment Scale (MoCA) is 30 points. The normal cut-off score is usually ≥ 26 points. To correct for the influence of educational level, if the educational duration of the subject is ≤ 12 years, 1 point will be added to their original score, with the maximum score remaining at 30 points.
Trial sites (1)
Facility
City
Region
Status
Qilu Hospital of Shandong University
Jinan
China
Recruiting
More Qilu Hospital of Shandong University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.